Aduro Biotech (NASDAQ: [[ticker:ADRO]]) has appointed Dimitry Nuyten to serve as its chief medical officer. Nuyten comes to Berkeley, CA-based Aduro from Pfizer (NYSE: [[ticker:PFE]]), where he was vice president and immuno-oncology clinical development leader. Prior to Pfizer, Nuyten was an executive at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]). Earlier this year, Aduro announced a corporate restructuring intended to turn its focus toward cancer drugs currently in clinical testing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
